Healthcare provider profile · identity verified

David Ryan Mullican, MD

Family Practice · SAN ANTONIO, TX · NPI 1518192475

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	440	157
Amlodipine Besylate	Amlodipine Besylate	280	98
Rosuvastatin Calcium	Rosuvastatin Calcium	271	97
Losartan Potassium	Losartan Potassium	268	93
Lisinopril	Lisinopril	237	84
Levothyroxine Sodium	Levothyroxine Sodium	228	72
Gabapentin	Gabapentin	152	65
Metformin Hcl	Metformin Hcl	150	54
Pantoprazole Sodium	Pantoprazole Sodium	149	53
Hydrochlorothiazide	Hydrochlorothiazide	148	50
Sertraline Hcl	Sertraline Hcl	142	55
Tamsulosin Hcl	Tamsulosin Hcl	137	53
Metoprolol Succinate	Metoprolol Succinate	132	46
Fluticasone Propionate	Fluticasone Propionate	123	58
Albuterol Sulfate Hfa	Albuterol Sulfate	121	57
Montelukast Sodium	Montelukast Sodium	121	46
Furosemide	Furosemide	95	34
Trazodone Hcl	Trazodone Hcl	92	33
Simvastatin	Simvastatin	88	28
Mounjaro	Tirzepatide	86	17
Carvedilol	Carvedilol	82	27
Clonazepam	Clonazepam	82	19
Duloxetine Hcl	Duloxetine Hcl	80	31
Metformin Hcl Er	Metformin Hcl	78	31
Prednisone	Prednisone	78	66
Omeprazole	Omeprazole	77	29
Pioglitazone Hcl	Pioglitazone Hcl	77	23
Famotidine	Famotidine	72	31
Clopidogrel	Clopidogrel Bisulfate	69	24
Tramadol Hcl	Tramadol Hcl	68	20
Naproxen	Naproxen	66	32
Triamcinolone Acetonide	Triamcinolone Acetonide	63	35
Metoprolol Tartrate	Metoprolol Tartrate	62	19
Diclofenac Sodium	Diclofenac Sodium	61	18
Nifedipine Er	Nifedipine	61	23
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	59	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	15
Finasteride	Finasteride	54	17
Alendronate Sodium	Alendronate Sodium	53	20
Eliquis	Apixaban	51	18
Tizanidine Hcl	Tizanidine Hcl	51	14
Trulicity	Dulaglutide	50	15
Pravastatin Sodium	Pravastatin Sodium	49	18
Valsartan	Valsartan	48	14
Pregabalin	Pregabalin	46	16
Buspirone Hcl	Buspirone Hcl	45	17
Celecoxib	Celecoxib	45	18
Doxycycline Hyclate	Doxycycline Hyclate	45	36
Jardiance	Empagliflozin	45	19
Glipizide	Glipizide	44	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	14
Bupropion Xl	Bupropion Hcl	43	17
Escitalopram Oxalate	Escitalopram Oxalate	43	15
Alprazolam	Alprazolam	41	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	41	39
Nystatin	Nystatin	40	11
Quetiapine Fumarate	Quetiapine Fumarate	40	11
Farxiga	Dapagliflozin Propanediol	38	suppressed
Potassium Chloride	Potassium Chloride	38	13
Ibuprofen	Ibuprofen	37	12
Allopurinol	Allopurinol	36	14
Oxybutynin Chloride Er	Oxybutynin Chloride	36	14
Acetaminophen-Codeine	Acetaminophen With Codeine	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	33	suppressed
Xarelto	Rivaroxaban	31	suppressed
Glimepiride	Glimepiride	30	11
Spironolactone	Spironolactone	30	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	13
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Ozempic	Semaglutide	29	11
Venlafaxine Hcl Er	Venlafaxine Hcl	29	suppressed
Mupirocin	Mupirocin	28	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	28	suppressed
Baclofen	Baclofen	25	suppressed
Cephalexin	Cephalexin	25	22
Januvia	Sitagliptin Phosphate	25	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	23
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Azithromycin	Azithromycin	23	22
Propranolol Hcl	Propranolol Hcl	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Ketoconazole	Ketoconazole	21	suppressed
Methocarbamol	Methocarbamol	21	suppressed
Amoxicillin	Amoxicillin	20	16
Meloxicam	Meloxicam	20	12
Nitroglycerin	Nitroglycerin	20	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Myrbetriq	Mirabegron	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Valacyclovir	Valacyclovir Hcl	17	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	16
Doxepin Hcl	Doxepin Hcl	16	suppressed
Estradiol	Estradiol	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Levemir Flexpen	Insulin Detemir	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Methylprednisolone	Methylprednisolone	14	13
Lidocaine	Lidocaine	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Atenolol	Atenolol	12	suppressed
Bydureon Bcise	Exenatide Microspheres	12	suppressed
Cefdinir	Cefdinir	12	12
Chlorthalidone	Chlorthalidone	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Lactulose	Lactulose	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	12
Diazepam	Diazepam	11	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error